BTIG analyst Justin Zelin raised the firm’s price target on 89bio to $37 from $30 and keeps a Buy rating on the shares. The firm notes that 89bio had “an eventful EASL 2023” with full data presentations in a late-breaking oral session and publication in the New England Journal of Medicine for the positive Phase 2b ENLIVEN trial of Pegozafermin in patients with Non-Alcoholic Steatohepatitis, or NASH, with F2/F3 fibrosis, and are in discussions with regulatory authorities slated for advancement into Phase 3 trials in the second half of 2023. The company also published data from the Phase 2 ENTRIGUE and has initiated the Phase 3 Study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ETNB:
- 3 Best Stocks to Buy Now, 7/3/2023, According to Top Analysts
- 89bio publishes results from Phase 2 ENTRIGUE trial of pegozafermin in SHTG
- 89bio presents data from ENLIVEN Phase 2b trial of pegozafermin in NASH
- 89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
- Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress